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Abstract
Background: Growth-enhancing hormone treatment is considered a possible intervention in
short but otherwise healthy adolescents. Although height gain is an obvious measure for evaluating
hormone treatment, this may not be the ultimate goal for the person, but rather a means to reach
other goals such as the amelioration of current height-related psychosocial problems or the
enhancement of future prospects in life and society. The aim of our study was to clarify the motives
of adolescents and their parents when choosing to participate in a growth-enhancing trial
combining growth hormone and puberty-delaying hormone treatment.
Methods: Participants were early pubertal adolescents (25 girls, 13 boys) aged from 11 to 13 years
(mean age 11.5 years) with a height standard deviation score (SDS) ranging from -1.03 to -3.43. All
had been classified as idiopathic short stature or persistent short stature born small for the
gestational age (intrauterine growth retardation) on the basis of a height SDS below -2, or had a
height SDS between -1 and -2 and a predicted adult height SDS below -2. The adolescents and their
parents completed questionnaires and a structured interview on the presence of height-related
stressors, parental worries about their child's behavior and future prospects, problems in
psychosocial functioning, and treatment expectations. Questionnaire scores were compared to
norms of the general Dutch population.
Results:  The adolescents reported normal psychosocial functioning and highly positive
expectations of the treatment in terms of height gain, whereas the parents reported that their
children encountered some behavioral problems (being anxious/depressed, and social and
attention problems) and height-related stressors (being teased and juvenilized). About 40% of the
parents were worried about their children's future prospects for finding a spouse or job. The
motives of the adolescents and their parents exhibited rather different profiles. The most prevalent
parental worries related to the current or future functioning of their children, while a few cases
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were characterized by no observed motives or by psychosocial problems only reported by the
adolescents themselves.
Conclusion: The motives for participating in a growth-enhancing hormone trial are more obvious
in the parents than in the adolescents themselves. Two out of three parents report worries about
the future opportunities or observe modest current psychosocial problems in their children. The
adolescents want to gain height, but the motivation underlying this remains unclear. Few of the
adolescents experience psychosocial problems. Our analyses revealed differences among
individuals in terms of motives, which implies that in an evaluation of hormone treatment, the
importance of divergent outcome variables will also differ among individuals. Effectiveness
evaluations of hormone treatment to increase height and the consequential fulfillment of other
goals must be awaited.
Background
Growth-enhancing hormone treatment is considered a
possible intervention in short but otherwise healthy ado-
lescents. Although height gain is an obvious measure for
evaluating hormone treatment, this may not be the ulti-
mate goal of the person, but rather a means to reach other
goals such as to ameliorate current height-related psycho-
social problems or to enhance future prospects in life and
society.
Psychosocial functioning has been emphasized in consid-
erations of the motives of children with idiopathic short
stature (ISS) and their parents seeking hormone treatment
to achieve a height gain. Children who have never been
medically referred do not seem to suffer from their stature
[1-4]. Most studies involving medically referred children
have revealed reduced social competence [5-14], while
internalizing and externalizing behavior, body image,
self-esteem, and scholastic competence have been shown,
on average, to be between normal and below normal [5-
8,10-17]. In addition to the possibility of improving psy-
chosocial functioning, several other factors are hypothe-
sized to motivate children and their parents to choose
hormone treatment, including the experience of height-
related psychosocial stressors (such as being teased or
juvenilized), future expectations for finding a spouse and
a desired career commensurate with intellectual potential
and interests, and the expectation of a treatment-induced
height gain.
Insight into the divergent motives at the time of choosing
hormone treatment is important, because it will help in
the choice of proper outcome measures for the evaluation
of a trial. Insight into motivational factors is especially
important in treatments combining biosynthetic growth
hormone (GH) with a puberty-delaying hormone,
because the possible benefits of enhancing growth must
be balanced against the possible negative psychosocial
consequences of delaying pubertal development. Moreo-
ver, such insight will clarify whether other treatments,
such as psychosocial counseling, should be employed to
solve current psychosocial problems and reach future
goals.
Our study examined 38 medically referred early pubertal,
short adolescents who agreed to participate in an experi-
mental trial of a combined treatment of GH and a
puberty-delaying hormone, and compared the results
with short adolescents who received no intervention. Par-
ticipants had a height standard deviation score (SDS)
below -2, or between -1 and -2 with a predicted adult
height SDS below -2, all without apparent underlying
pathology. Twenty-six of the subjects had a normal birth
weight and length and were classified as ISS [18], while 12
were born small for gestational age (SGA) [19,20]. Both
ISS and SGA have been associated with problems in
behavior, social functioning, school competence, and
attention [21-23], while SGA has also been associated
with lowered intelligence and minor neurologic dysfunc-
tions [21,22,24].
With the aim of clarifying the motives of parents and chil-
dren for participation in the trial, we examined the base-
line scores of the adolescents on the following
psychosocial factors before initiating the treatment: pres-
ence of height-related stressors, parental worries about the
child's behavior and future prospects, self-reported prob-
lems in psychosocial functioning, and treatment
expectations.
Methods
Study population and procedures
The inclusion criteria for participation in the study were as
follows: being in early puberty as documented by Tanner
breast stage 2 or 3 for girls and Tanner genital stage 2 or 3
for boys; an actual height SDS for the same age and sex of
less than -2.0, or a height SDS between -1.0 and -2.0 with
a predicted adult height of more than -2.0 SDS; a chrono-
logical age and bone age of less than 12 years for girls and
13 years for boys; a documented GH response of >20 mU/
L (>10 ug/L) after a standard provocation test and/or dur-
ing a sleep test; a ratio of sitting height/subischial legBMC Pediatrics 2005, 5:15 http://www.biomedcentral.com/1471-2431/5/15
Page 3 of 11
(page number not for citation purposes)
height between the 3rd and 97th percentiles; and normal
blood tests and urinalysis.
The study population consisted of 38 early pubertal ado-
lescents (25 girls,13 boys) aged from 11 to 13 years (mean
age 11.5 years). Most of the cohort (17 girls, 9 boys) had
a normal birth size and were classified as ISS. Twelve ado-
lescents (8 girls, 4 boys) were known to have had a birth
length of more than 2 SD below the mean for gestational
age and were classified as short-stature-born SGA. The
most likely reason for the girls substantially outnumber-
ing the boys is that the combination of short stature and
early puberty is more common in girls than boys. The
mean height of the adolescents was 134.9 (5.8) cm, with
a range of 120.0–148.5 cm, corresponding to a height SDS
ranging from -1.03 to -3.43. There were nine adolescents
with an actual height SDS between -1.0 and -2.0 and a pre-
dicted adult height SDS of less than -2.0.
The following four Dutch hospitals participated in this
multi-center study: the University Medical Center Utrecht-
Wilhelmina Children's Hospital, the VU University Medi-
cal Center Amsterdam, the Sophia Children's Hospital
Rotterdam, and the Catharina Hospital Eindhoven [19].
The first 40 referred adolescents who fulfilled the inclu-
sion criteria and agreed to participate after having been
informed about the study participated in our randomized
controlled trial with puberty-delaying gonadotropin-
releasing hormone agonist (GnRHa) therapy in combina-
tion with GH therapy or no therapeutic intervention.
Twenty of the adolescents were randomly selected to
receive the combination therapy for three years, while the
other 20 adolescents were to receive no treatment. Imme-
diately after randomization, two participants (one from
the treatment group and one from the control group)
decided to stop participation.
The experimental trial examined the hypothesis that the
combination of GH and GnRHa for three years would
increase the final height in comparison with untreated
controls [19]. For three years the adolescents in the treat-
ment group were given GH daily by subcutaneous injec-
tion of 4 IU (1.33 mg) per square meter body surface;
(Genotropin, Pharmacia, Sweden; now Pfizer, New York,
USA) and a depot preparation of 3.75 mg of GnRHa
(Decapeptyl-CR, Ferring, Sweden) every four weeks intra-
muscularly. The adolescents in the control group were fol-
lowed yearly to document their growth and pubertal
development [19]. Before treatment, and at one, two, and
three years after beginning the treatment, the adolescents
and the parents of both the treatment and control groups
filled out questionnaires to assess the psychosocial func-
tioning of the adolescents. The parents were also
interviewed.
A skilled psychologist examined the adolescents and their
parents in the interval between randomization and start-
ing treatment. This interval was chosen for ethical reasons
to avoid the suggestion that the answers of the parents or
adolescents might affect the group allocation. Moreover,
providing knowledge of the result of the randomization
procedure to both parents and adolescents was assumed
to make them better able to give unbiased responses to the
questionnaires and interview. The adolescents filled out
questionnaires on perceived competence, psychological
distress, body image, self-image, and personality charac-
teristics. The parents filled out questionnaires regarding
emotional and behavioral problems of their children, and
were interviewed by a psychologist.
The medical ethics committees at the four participating
centers approved the study. The parents of all children
provided written informed consent before participation.
Measures
Parental reports
A structured interview was conducted with parents to
assess the adolescents' health-related development, cur-
rent height-related stressors, and parental concerns about
their child's future. Parents were asked about health prob-
lems, the child's age at which a physician was consulted
for the first time because of the growth retardation, and
who initiated the referral (school doctor, family doctor, or
pediatrician). In order to determine the height-related
psychosocial stressors encountered by the adolescents, the
parents were asked whether their children were teased or
juvenilized by other children. To find out parental worries
about the future of their child, parents were asked whether
they considered that the prospects of their child were
equal to that of persons of normal height in the labor mar-
ket and finding a spouse (yes, doubtful, no).
To assess behavioral and emotional problems, the parents
filled out the Child Behavior Check List (CBCL) [25]. This
questionnaire consists of the following eight syndrome
areas (the so-called narrow-band scales): withdrawn
behavior, somatic complaints, anxious/depressed behav-
ior, social problems, thought problems, attention prob-
lems, delinquent behavior, and aggressive behavior. The
scores of the subscales were summarized into a score for
internalizing and externalizing problems, and a total
problem score (the so-called broad-band scales).
The Silhouette Apperception Technique (SAT) has been
shown to be a valid and useful instrument for assessing
perceptions of the present and future heights of adoles-
cents [7,26-28]. The parents were shown drawings of peo-
ple of different heights, corresponding proportionally
with the heights of the 3rd, 25th, 50th, 75th, and 97th
percentiles, and asked to identify the drawings that theyBMC Pediatrics 2005, 5:15 http://www.biomedcentral.com/1471-2431/5/15
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thought best fit the current and future heights of their
child.
Adolescents' self-reports
The adolescents completed a global intelligence test and a
series of questionnaires regarding perceived competence,
psychological distress, and personality characteristics.
The Dutch versions of the Self-Perception Profile for Chil-
dren (CBSK) and the Self-Perception Profile for Adoles-
cents (CBSA) were used [29,30]. The CBSK consists of six
perceived competence subscales: scholastic competence,
social acceptance, athletic competence, physical appear-
ance, behavior and conscience, and global self-worth. The
CBSA consists of these six scales plus the scales of friend-
ship and romantic love. In our study we only used the six
scales that the CBSK and the CBSA have in common.
Anxiety was measured using the Dutch version of the
State-Trait Anxiety Inventory for Children (ZBV-K), with
the subscales of state anxiety and trait anxiety [31].
Depressive mood was assessed by the KDVK (Dutch Short
Depression Questionnaire for Children) [32].
Personality characteristics of the adolescents were investi-
gated using the Dutch Personality Questionnaire-Junior
(NPV-J), with five subscales: inadequacy, perseverance,
social inadequacy, recalcitrance, and dominance [33].
The SAT was used to measure perceptions of the present
and future heights of the adolescents [7,26-28].
Intelligence was assessed by the Dutch short version of the
Wechsler Intelligence Scale for Children (Revised) (WISC-
Rn) [34].
Data analyses
Standard deviation scores (SDS) were used to compare the
results of the quantitative questionnaires with the means
of the general Dutch population. This was performed by
subtracting the mean score of the norm group of the same
age and sex from the score of the participants, with this
difference divided by the SD of the norm group. This score
expresses how much each study subject deviates from the
norm in SD units. T-tests examined whether these age-and
sex-adjusted scores significantly deviated from zero (i.e.,
from the norm).
To categorize groups of adolescents with divergent
motives for wanting hormone treatment, we formed sub-
groups based on the presence of height-related stressors
(being teased or juvenilized), parental worries about
future prospects (regarding finding a spouse or job),
parental worries about their child's behavior (internaliz-
ing or externalizing problems), and self-reported prob-
lems in psychosocial functioning (low self-esteem,
anxiety, or depressive mood). The cut-off score for having
externalizing or internalizing problems was a norm devi-
ation score of 1 SD higher than the mean for the same age
and sex on the CBCL scales for internalizing and external-
izing behavioral problems. This score corresponds with a
CBCL T-score of 60 (84th percentile) in the healthy norm
group, and conforms with CBCL standards for the border-
line range of clinical problems [25]. The cut-off score for
anxiety and low self-esteem was a norm deviation score of
at least 1 SD higher (anxiety) or lower (self-esteem) than
the means for the same age and sex on the trait anxiety
and the global self-worth scale, respectively. The cut-off
score for indicating clinical signs of depression was a raw
score of 4 points or more on the depression scale [32].
Our study group was small and significant differences
were generally not evident in the results between boys and
girls, between adolescents with ISS and those born SGA,
and between adolescents who were to receive hormone
treatment and those who were not. Hence our report
focuses primarily on the results for the whole group.
Results
Medical referral
The mean age of the child when a physician was consulted
for the first time because of the growth retardation was 7.3
years (SD = 3.5 years). Medical referral was initiated by the
family physician (53%; seven adolescents with SGA, thir-
teen with ISS) or school physician (23.5%; two adoles-
cents with SGA, seven with ISS), whereas some of the
adolescents were already under supervision of a pediatri-
cian as young children because of health problems other
than short stature (23.5%; three adolescents with SGA, six
with ISS). Ninety percent of the parents reported that their
children had never experienced serious health problems.
Height-related psychosocial stressors and future 
expectations
Approximately one-quarter (28%) of parents reported
that their child was teased by peers because of short stat-
ure (15% of boys, 35% of girls), and 14% of parents
reported that their child was juvenilized by peers (23% of
boys, 9% of girls). All but one adolescent took part in
gymnastic lessons at school (97%).
Regarding the effects of short stature on future expecta-
tions, 44.5% of the parents expected their child to have a
lower prospect in the labor market as an adult (39% of
boys, 48% of girls), and 39% expected their child to have
a lower prospect of finding a spouse (77% of boys, 17%
of girls). This difference between boys and girls was signif-
icant (p < 0.01). No other significant differences between
boys and girls were found.BMC Pediatrics 2005, 5:15 http://www.biomedcentral.com/1471-2431/5/15
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Psychosocial functioning
Parental reports
On parental ratings of behavioral difficulties as measured
by the CBCL, the short adolescents exhibited higher scores
than the general Dutch norm group on the broad-band
scales of internalizing problems (p  < 0.05) and total
behavioral problems (p < 0.05) (Table 1). The elevated
score for withdrawn behavior was marginally significant
(p < 0.10), while the higher score for anxious/depressed
behavior was significant (p < 0.05). These narrow-band
scales are summarized in the internalizing scale. The short
adolescents also exhibited higher than normal scores on
the social problems (p = 0.01) and attention problems (p
< 0.05) scales. The scores deviated by 0.50–0.73 SDS from
the norm (see Table 1), which reflects moderate effects.
Three adolescents were in the clinical range for internaliz-
ing problems (CBCL T-score of 63; 90th percentile). The
short adolescents did not score significantly higher than
the norm group on the narrow-band scales of somatic
complaints, thought problems, delinquent behavior and
aggressive behavior, or the broad-band scale of externaliz-
ing problems. One adolescent scored in the clinical range
for externalizing behavior.
To clarify the nature of the problems perceived by the par-
ents, we examined specific items on the CBCL scales
where parents observed significant problems. Items for
which the adolescents deviated at least moderately from
the norm included generic items on the scale of anxious/
depressed behavior, height-related items on the scale of
social problems, and both generic and height-related
items on the scale of attention problems (for the specific
items, see Table 2).
Adolescents' self-reports
Virtually none of the scores of the short adolescents on
self-reported questionnaires differed significantly from
the norm group (Table 3). Adolescents with ISS or SGA
did not deviate from the norm group with respect to per-
ceived competence and psychological distress. Indeed,
their perceived social acceptance was higher than that in
the norm group (p = 0.05). With respect to personality
characteristics, adolescents with ISS or SGA described
themselves to be more persistent (quiet, conscientious,
and diligent) than the norm group (p < 0.05). Two adoles-
cents were in the clinical range (deviation of more than
2SDs) for global self-worth. One adolescent was at the
clinical level for trait anxiety.
Cognitive functioning
Intelligence scores (corrected total WISC-Rn scores)
ranged from 66 to 128, with a mean score of 99.8. Six ado-
lescents (three ISS, three SGA) had an intelligence lower
than 80. The intelligence did not differ significantly
between adolescents with ISS and those with SGA.
Expectations of hormone treatment: perception of current 
and future heights
Perceptions of current and future heights were analyzed
separately in adolescents who were to receive hormone
treatment and those who were not (Table 4). Most parents
and adolescents in both the treatment and control groups
estimated the current height of the adolescent at the 3rd
percentile of the population references, which corre-
sponds well to their actual height. Parents of the
adolescents in the treatment group expected a greater
future height than the parents of the adolescents in the
control group (Z = -2.68, p = 0.007). None of the other
Table 1: Emotional and behavioral problems of 34 adolescents with short stature as judged by their parents.
Variable d SD tp
Withdrawn behavior 0.34 1.10 1.82 0.08
Somatic complaints 0.38 1.34 1.66 0.11
Anxious/depressed behavior 0.54 1.35 2.35 0.03 *
Social problems 0.73 1.44 2.96 0.01 **
Thought problems 0.26 1.00 1.49 0.15
Attention problems 0.59 1.36 2.54 0.02 *
Delinquent behavior 0.29 1.46 1.18 0.25
Aggressive behavior 0.26 1.03 1.47 0.15
Internalizing problems 0.54 1.31 2.42 0.02 *
Externalizing problems 0.28 1.17 1.40 0.17
Total behavioral problems 0.50 1.25 2.35 0.03 *
Mean scores (d), standard deviations (SD), and t and p values. The d values reflect the deviations from the Dutch normative population in standard 
deviation units, where a positive score indicates that the adolescents with short stature are judged to have more problems than the norm group.
The d values have the following common effect sizes: a value smaller than 0.2 reflects no deviation from the norm, while values between 0.2 and 0.5, 
between 0.5 and 0.8, and greater than 0.8 reflect small, moderate, and large deviations, respectively [42]. T-tests examined whether norm deviation 
scores deviated from zero (the norm).
* p < 0.05, ** p < 0.01BMC Pediatrics 2005, 5:15 http://www.biomedcentral.com/1471-2431/5/15
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comparisons between the experimental and control
groups revealed significant differences.
Groups classified according to motives
To provide a summary description, four groups of adoles-
cents were distinguished based on the presence of height-
related stressors, parental worries about future prospects,
parental worries about their children's behavior, and self-
reported problems in psychosocial functioning (Table 5).
Group 1 consisted of four adolescents and their parents
(12%) who did not report any psychosocial problems.
However, all adolescents in this group reported having
high expectations of the treatment in terms of height gain
(these data are not listed in Table 5).
Group 2 consisted of 11 adolescents (32%) whose parents
reported height-related psychosocial stressors or worries
about future prospects, but no problems in psychosocial
functioning (parental or adolescents' reports).
Group 3 consisted of 11 adolescents (32%) whose parents
reported problems in psychosocial functioning as well as
worries about future prospects and in most cases the pres-
Table 2: Scores at separate items of the CBCL scales anxious/depressed behavior, social problems, and attention problems.
Item d SD tp
Anxious/depressed behavior:
112. Worries 0.83 1.36 3.55 0.001 **
45. Nervous, highstrung, or tense 0.65 1.25 3.03 0.005 **
35. Feels worthless or inferior 0.63 1.66 2.22 0.03 *
50. Too fearful or anxious 0.42 1.53 1.59 0.12
12. Complaints of loneliness 0.37 1.49 1.44 0.16
32. Feels he/she has to be perfect 0.35 1.03 1.98 0.06
103. Unhappy, sad, or depressed 0.33 1.21 1.57 0.13
14. Cries a lot 0.19 1.30 0.86 0.40
52. Feels too guilty 0.14 1.47 0.54 0.59
33. Feels or complaints that no one loves him/her 0.11 1.08 0.60 0.55
71. Self-conscious or easily embarrassed 0.11 1.19 0.53 0.60
89. Suspicious 0.08 0.98 0.45 0.65
31. Fears he/she might think or do something bad -0.03 0.89 -0.21 0.84
34. Feels others are out to get him/her -0.11 0.80 -0.83 0.41
Social problems:
64. Prefers being with younger kids 1.06 1.67 3.71 0.001 **
38. Gets teased a lot 0.91 1.38 3.86 0.000 **
1. Acts too young for his/her age 0.65 1.39 2.73 0.010 **
11. Clings to adults or too dependent 0.30 1.31 1.33 0.19
55. Overweight 0.03 1.00 0.20 0.85
48. Not liked by other kids -0.08 0.81 -0.58 0.57
62. Poorly coordinated or clumsy -0.10 0.75 -0.75 0.46
25. Doesn't get along with other kids -0.15 0.57 -1.56 0.13
Attention problems
1. Acts too young for his/her age 0.65 1.39 2.73 0.010 **
45. Nervous, highstrung, or tense 0.65 1.25 3.03 0.005 **
8. Can't concentrate, can't pay attention for long 0.42 1.20 2.07 0.047 *
46. Nervous movements or twitching 0.39 1.55 1.48 0.15
41. Impulsive or acts without thinking 0.31 1.23 1.48 0.15
13. Confused or seems to be in a fog 0.24 1.27 1.12 0.27
61. Poor school work 0.17 1.23 0.82 0.42
10. Can't sit still, restless, or hyperactive 0.15 0.99 0.90 0.37
17. Day-dreams or gets lost in his/her thoughts 0.14 1.05 0.77 0.45
80. Stares blankly 0.06 1.11 0.31 0.76
62. Poorly coordinated or clumsy -0.10 0.75 -0.75 0.46
Mean scores (d), standard deviations (SD), and t and p values. The d values reflect the deviations from the Dutch normative population in standard 
deviation units, where a positive score indicates that the adolescents with short stature are judged to have more problems than the norm group.
The d values have the following common effect sizes: a value smaller than 0.2 reflects no deviation from the norm, while values between 0.2 and 0.5, 
between 0.5 and 0.8, and greater than 0.8 reflect small, moderate, and large deviations, respectively [42]. T-tests examined whether norm deviation 
scores deviated from zero (the norm). * p < 0.05, ** p < 0.01
Note that some items of the CBCL load on more than one scaleBMC Pediatrics 2005, 5:15 http://www.biomedcentral.com/1471-2431/5/15
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ence of height-related psychosocial stressors. The adoles-
cents themselves did not report problems in psychosocial
functioning.
Group 4 consisted of eight adolescents (24%) who
reported problems in psychosocial functioning, while
their parents did not report height-related psychosocial
Table 3: Psychological functioning and distress as reported by the adolescents with short stature.
Variable nd SD tp
Perceived competence (CBSK):
Scholastic competence 31 0.15 1.06 0.78 0.45
Social acceptance 31 0.37 1.00 2.04 0.05 *
Athletic competence 31 0.22 1.11 1.08 0.29
Physical appearance 31 -0.21 0.98 -1.22 0.23
Behavior/conscience 31 0.17 1.05 0.90 0.38
Global self-worth 31 0.02 1.08 0.07 0.94
Psychological distress (ZBV-K):
State anxiety 37 -0.01 1.06 -0.08 0.94
Trait anxiety 37 0.09 1.12 -0.52 0.61
Personality characteristics (NPV-J):
Inadequacy 38 -0.08 0.88 -0.52 0.61
Perseverance 38 0.34 0.95 2.20 0.03 *
Social inadequacy 38 0.05 0.82 0.36 0.72
Recalcitrance 38 -0.05 0.97 -0.32 0.75
Domination 38 0.23 1.07 1.34 0.19
Mean scores (d), standard deviations (SD), and t and p values. The d values reflect the deviations from the Dutch normative population in standard 
deviation units, where a positive score indicates that the adolescents with short stature judged themselves to have higher perceived competence, 
more anxiety, and a higher score on personality scales than the norm group, respectively.
The d values have the following common effect sizes: a value smaller than 0.2 reflects no deviation from the norm, while values between 0.2 and 0.5, 
between 0.5 and 0.8, and greater than 0.8 reflect small, moderate, and large deviations, respectively [42]. T-tests examined whether norm deviation 
scores deviated from zero (the norm).
* p < 0.05, ** p < 0.01
Table 4: Current and future heights as perceived by adolescents and their parents on the Silhouette Apperception Technique
Treatment group (n = 19) Current height (%) Future height (%)
Percentile Adolescents Parents Adolescents Parents
3rd 52.6 88.9 5.3 0.0
25th 36.8 5.6 15.8 38.9
50th 5.3 5.6 26.3 38.9
75th 0.0 0.0 42.1 11.1
97th 5.3 0.0 10.5 11.1
Control group (n = 19) Current height (%) Future height (%)
Percentile Adolescents Parents Adolescents Parents
3rd 47.4 77.8 15.8 50.0
25th 47.4 16.7 26.3 22.2
50th 5.3 5.6 15.8 11.1
75th 0.0 0.0 42.1 16.7
97th 0.0 0.0 0.0 0.0BMC Pediatrics 2005, 5:15 http://www.biomedcentral.com/1471-2431/5/15
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stressors and worries about future prospects, and in most
cases did not report behavioral problems.
Discussion
In a medically referred group of early pubertal adolescents
with ISS or SGA, the motivation of the adolescents and
their parents for choosing hormone treatment was inves-
tigated before initiating a combined GH and puberty
delaying hormone treatment.
Parental reports revealed that current height-related psy-
chosocial stressors were not the main reason for wanting
growth-enhancing hormone treatment. Some of the par-
ents reported that their children were teased (28%) or
juvenilized (14%) because of their stature. These findings
are close to those from another Dutch study [7], but in
contrast with an American study that showed teasing and
juvenilizing rates of 50% and 70%, respectively [14].
According to their parents, most of the adolescents in the
present study were relatively free of current stressors. More
than 40% of the parents expected that their children
would have a decreased prospect in the labor market or
difficulties in finding a spouse. This suggests that the
motivation of providing opportunities for the future of
the adolescents was a compelling reason for parents to
choose hormone treatment.
Another possible reason for wanting hormone treatment
is parental worries about the psychosocial functioning of
their children. On average, as judged by their parents, the
adolescents encountered internalizing symptoms, such as
anxious or depressed tendencies, as well as social and
attention problems. These problems were of a moderate
magnitude compared to Dutch norms. It is likely that our
analysis overestimated the actual psychosocial
dysfunctioning, because the normative criteria were based
on a very healthy group: any child who had been referred
to a mental-health professional in the past 12 months, or
who was currently receiving special educational services,
was excluded from the normative sample [25,35]. Moreo-
ver, some of these problems are height-related issues that
need not be a behavioral problem, such as preferring to be
with younger kids or acting too young for his/her age.
The perceptions of adolescents about their own psychoso-
cial functioning did not confirm the parental worries. The
adolescents reported normal competence and personality,
and even higher competence on social acceptance and
perseverance, and little distress. This raises the question of
whether adolescents or their parents are the best judges
about well-being and functioning of adolescents. Adoles-
cents may be unreliable informants because they are too
young to give an adequate assessment of their own func-
tioning, lack a time perspective, or have a tendency toward
denial, while parents may be unreliable because of
unrealistic anxieties about the health, future, and behav-
ior of their children [36,37]. Our observation of more psy-
chosocial problems being reported by parents than
adolescents suggests that the perception of psychosocial
problems is a stronger motive for parents than for adoles-
cents when choosing to participate in the hormone treat-
ment trial.
The perception of the current height of the adolescents
was accurate in the majority of parents, while several ado-
lescents had a tendency to overestimate their current
Table 5: Classification of adolescents based on motives
Parental reports Self-reports
Height-related stressors Worries about future prospects Behavioral problems Psychosocial problems
Group 1 (n = 4) - - - -
Group 2a (n = 3) - + - -
Group 2b (n = 4) + - - -
Group 2c (n = 4) + + - -
Group 3a (n = 4) - + + -
Group 3b (n = 7) + + + -
Group 4a (n = 6) - - - +
Group 4b (n = 2) - - + +
The presence or absence of a motive is indicated by '+' and '-', respectively; motives include parental reports of the presence of height-related 
stressors (being teased or juvenilized), worries about future prospects (finding a spouse or job), and behavioral problems (internalizing or 
externalizing problems), and self-reporting of psychosocial problems (anxiety, low self-worth, or depressive mood). The four missing cases are due 
to one of the classifying variables being missing.BMC Pediatrics 2005, 5:15 http://www.biomedcentral.com/1471-2431/5/15
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height. Consistent with previous observations [26,38],
several adolescents who were to receive hormone treat-
ment had unrealistic expectations of their future height
(as did their parents). Even those who were not to receive
hormone treatment had high expectations of their future
height. Optimism, even when unrealistic, has been shown
to motivate the choice for a treatment and its adherence
once started in several diseases [39,40]. However, unreal-
istic expectations may also be associated with a poor psy-
chosocial outcome, as has been demonstrated in persons
seeking cosmetic surgery, for example [41].
The tentative breakdown of subgroups provides a descrip-
tive summary of four rather different profiles of motives
for hormone treatment in the adolescents and their par-
ents. A small group of adolescents and their parents
reported no psychosocial problems. Highly positive treat-
ment expectations of the adolescents in terms of height
gain was the only detected motive, with the underlying
reason remaining unclear. Perhaps it predominantly
reflects the developmental wish of any child to want to
grow (up). The parents reported height-related stressors or
psychosocial problems and in most cases these worries
about current problems were accompanied by worries
about future prospects. The final group consisted of ado-
lescents who reported problems in their psychosocial
functioning, while their parents did not necessarily
observe problems and were not worried. The cause of
these problems and the relation with height remain
unclear. In choosing such an intensive hormone treat-
ment involving daily injections, pubertal delay, and pos-
sible side effects, we would have expected at least a
subgroup of cases to show a motivation in parents as well
as adolescents. However, none of the adolescents exhib-
ited elevated scores on all motives, and only two pairs of
parents and adolescents were congruent with respect to
the observation of psychosocial problems. In the majority
of cases it was either the parents or the adolescents who
reported one or more motives.
Our sample size was sufficiently large to allow conclu-
sions to be drawn regarding the comparison with norma-
tive data, but a larger sample size is needed for examining
with sufficient power the possible roles of gender, type of
short stature, and risks and protective factors that may
modulate the psychosocial functioning of these adoles-
cents [42].
Conclusion
Our study demonstrates that the motives of parents to let
their children participate in a growth-enhancing hormone
trial are more obvious than the motives of the early puber-
tal adolescents themselves. Two out of three parents
reported worries about the future opportunities or
observed modest current psychosocial problems in their
children. The adolescents wanted to gain height, but the
underlying motivation remains unclear. Few of the ado-
lescents experienced psychosocial problems. Our analyses
showed that motives varied among individuals. This
result implies that when evaluating hormone treatment,
the importance of divergent outcome variables will also
differ among individuals. Effectiveness evaluations of hor-
mone treatment to increase height and the consequential
fulfillment of other goals must be awaited.
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